Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in metastatic or unresectable urothelial cancer
NCT02387996Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2015
- Primary completion
- Apr 2016
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of nivolumab in urothelial carcinoma (UC), sponsored by Bristol Myers Squibb. Started Mar 2015; status: completed.
02
Drugs
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02387996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02387996.